Lei Shi

Biography

I have been engaged in the clinical and management of prostate cancer for 17 years. From 2017 to 2020, I worked as a postdoctoral fellow at the Mayo Clinic Prostate Cancer Research Center, the No. 1 in the United States. My main research direction is castration-resistant prostate cancer cells. Metabolism and regulation of enzymes related to androgen synthesis. He has fully mastered the skills of experimental design, experimental operation, data analysis and transformation of results, and has team leadership skills. His work results during the postdoctoral period have been recognized by the head of the Mayo Clinic Prostate Cancer Research Laboratory and praised by colleagues. The applicant presided over and participated in 3 provincial and National Natural Science Foundation youth projects related to this project, and published more than 10 SCI articles. In 2021, as the first author, he will publish 1 SCI-indexed article in Cancer Research, revealing for the first time the expression and regulatory mechanism of 17βHSD4 in SPOP-mutated prostate cancer; and as the co-corresponding author, he will publish 1 SCI-indexed article in Nature Communications, focusing on Changes in androgen receptor expression in Enzalutamide-resistant prostate cancer cells were investigated. Participated as the main member of the project BET-CBP/p300 acetyltransferase inhibitor NEO2734 has activity on SPOP mutant prostate cancer. In 2019, 1 SCI article was published in EMBO Mol Med. He has participated in domestic and foreign academic conferences for many times, and has conducted in-depth research on the biological characteristics of castration-resistant prostate cancer cells and the regulation of intracellular androgen metabolism, and has a full grasp of the cutting-edge directions.